Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) reports the results of its Annual General Meeting (AGM) and a separate General Meeting held on May 8, 2019. The filing details shareholder voting outcomes on corporate governance matters, director elections, and a specific transaction approval.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on corporate governance and voting statistics rather than financial performance.
Material Changes and Voting Results
All resolutions presented at both the AGM and the General Meeting were passed by shareholders. Key voting outcomes include:
- Annual Report Adoption: Resolution 1 to receive and adopt the 2018 Annual Report passed with 99.95% of votes cast in favor.
- Remuneration Report: Resolution 2 to approve the Annual report on remuneration passed with 88.77% of votes cast in favor, representing the lowest approval rate among standard resolutions.
- Director Elections: All director election and re-election resolutions passed with approval rates ranging from 96.46% (Urs Rohner) to 99.52% (Dr Laurie Glimcher).
- Strategic Transaction: The sole resolution at the General Meeting, approving the transaction between GSK, GlaxoSmithKline Consumer Healthcare Holdings Limited, and Pfizer, Inc., passed with 99.85% of votes cast in favor.
- Board Changes: Simon Dingemans did not stand for re-election and retired from the Board effective the conclusion of the AGM. He will receive fees for service but no payment for loss of office.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on financial risks, or contingencies. The document confirms that the transaction with Pfizer was approved for the purposes of Chapter 11 of the Listing Rules of the Financial Conduct Authority.
Investor Verification Checklist
- Verify the full text of the 2018 Annual Report and Remuneration Report referenced in the voting results.
- Review the Circular to Shareholders and Notice of General Meeting for details on the Pfizer transaction approved at the General Meeting.
- Confirm the updated Board composition following the retirement of Simon Dingemans and the election of new directors.
- Check the GSK website for the full poll results and the submission of resolutions to the UK Listing Authority.